FDA has approved MI Cancer Seek for use as a companion diagnostic to identify patients with cancer who may benefit from treatment with targeted therapies.
AML Express, a next-generation sequencing assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia, was announced by NeoGenomics Inc.
Myriad Genetics Inc. and Ultima Genomics Inc. join to explore Ultima’s UG 100 sequencing platform and its ppmSeq technology to advance Myriad’s ability to offer groundbreaking clinical tests. Myriad has purchased a new UG 100 that will soon join other leading sequencing platforms in its Lab of the Future facility in South San Francisco.
Labcorp announced an expanded collaboration with Ultima Genomics to utilize its UG 100TM sequencing solution and ppmSeqTM technology to explore new whole genome sequencing clinical applications, including molecular residual disease in patients with early-stage solid tumor cancers.
The initial foray into genomic sequencing two decades ago has led to the discovery of key driver mutations and spurred drug development, thereby transforming the management of imminently lethal diseases.
Strata Oncology Inc announced the integration of discrete genomic data from its StrataNGS NGS-based tumor profiling with the University of Wisconsin Carbone Cancer Center and UW Health Epic genomics module.
European regulators have prohibited the already-implemented $7.1 billion merger of Illumina and GRAIL, stating that the deal “would have stifled innovation, and reduced choice in the emerging market for blood-based early cancer detection tests.”
Ultima Genomics is developing a high-throughput, low-cost sequencing platform that delivers $100 genome sequencing. Ultima has secured approximately $600 million in backing.
Thermo Fisher Scientific launched the CE-IVD marked Ion Torrent Genexus Dx Integrated Sequencer, an automated next-generation sequencing platform that delivers results in as soon as 24 hours.
A study led by Susan G. Komen Brinker Award winner Carlos Caldas found that there may be a way to predict treatment response in breast cancer patients even before treatment begins. Results will be presented at the 2021 San Antonio Breast Cancer Symposium Dec. 7-10.
